NCT02069119View on ClinicalTrials.gov

A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Atrial Fibrillation
Interventions
DRUG

OPC-108459

DRUG

Placebo

Trial Locations (1)

Unknown

Kyushu Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT02069119 - A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF) | Biotech Hunter | Biotech Hunter